Though no single drug is a “game-changer,” medications and improved standard care seem to be reducing death rates.
If most of us are confused about all the updates swirling COVID-19, imagine what it’s like for Adarsh Bhimraj. Not only has this Cleveland Clinic physician had to contend with a growing caseload, he’s part of a 16-person team in charge of managing the Infectious Diseases Society of America’s guidelines for treating COVID-19.
Between caring for patients at the Ohio hospital and even coming down with a mild case of coronavirus himself, Bhimraj has had to assess a steady stream of new information on how to treat the virus. Researchers around the world are conducting more than a thousand randomized clinical trials testing COVID-19 treatments. Bhimraj and his colleagues on the guidelines panel must navigate through this torrent and highlight the most promising results.
Uncertain though it still may be, knowledge of how the coronavirus works and how to fight it is slowly, surely accreting. Eight months into the pandemic, doctors are gaining a better handle on how to treat the disease. Some therapies are brand-new medications, while others are common medical staples previously shown in clinical trials to be safe and effective for different ailments. Other improvements have come from subtle changes to standard care. All of it, bit by bit, is saving lives.
“None of these therapies are, in Fauci’s words, ‘game-changers,’ right?” Bhimraj says, referencing statements made by Anthony Fauci, the director of the U.S. National Institute of Allergy and Infectious Diseases. “But they certainly show a signal that they could be helpful.”
Of the hundreds of research efforts seeking to validate COVID-19 remedies, one based at the University of Oxford appears to be the early standard-bearer when it comes to separating hope from hype. The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial is an extensive effort within the United Kingdom to test treatments for COVID-19.
One of the drugs among the array of possible treatments being tested is the steroid dexamethasone. COVID-19 can trigger an overzealous immune response, and like other steroids, dexamethasone can blunt and modify such a reaction. On June 16, the team published their early results about dexamethasone, which showed that among COVID-19 patients requiring oxygen or mechanical ventilation, dexamethasone cut the risk of death by a third, compared to standard therapy alone. For people with milder cases who don’t need oxygen support, dexamethasone doesn’t seem to help—and might even make things worse. But in the most severe cases, dexamethasone represents a potential lifeline.
“We announced results at lunchtime, and by teatime here, the chief medical officers here in the U.K. went to every hospital, saying they should adopt this as standard practice,” says Oxford cardiologist Martin Landray, a co-lead investigator on the RECOVERY trial. “And although I can’t prove it, I think it’s pretty certain that by the weekend, lives are being saved as a result of that.”
On June 25, the Infectious Diseases Society of America updated its treatment guidelines to conditionally recommend dexamethasone, and the U.S. National Institutes of Health followed suit in its own guidelines. Though dexamethasone isn’t technically an FDA-approved medication for COVID-19 (no drug is), the steroid was the first medication shown to boost COVID-19 survival. Demand for the inexpensive drug—which costs about $25 per bottle—has risen so much, so quickly, U.S. pharmacists are reporting shortages.
One early advance in the broader hunt for treatments involved remdesivir, a repurposed antiviral that can slightly shorten COVID-19 recovery time. But researchers are also looking into ways to ramp up the body’s natural antiviral response. One potential avenue: interferon-beta, a protein involved in the human immune system.
Normally, when a cell is infected by a virus, it releases many versions of interferons that tell neighboring cells to switch on their germ defense and produce a cocktail of antiviral compounds. However, SARS-CoV-2 appears to be good at sneaking around these interferon tripwires. As a result, the initial response in the lungs doesn’t fully rev up, letting the virus run roughshod.
News of this pattern caught the attention of Synairgen, a U.K. biotechnology company. For years, Synairgen has been developing a breathable mist of interferon-beta to help severe asthma and chronic obstructive pulmonary disease patients better fight off viral infections.
In a July 20 presentation to investors, Synairgen representatives said that in a randomized trial with 101 hospitalized subjects, patients on interferon-beta were 79 percent less likely to die of the disease or require invasive ventilation than patients on standard care. Patients who received interferon-beta also recovered in greater numbers and reported less shortness of breath.
Whiz-bang pharmaceuticals aren’t the only source of hope in treating COVID-19. Just as important are basic preventions—masks, social distancing, hand washing—as well as improvements in standard care. The greater understanding doctors now have of the disease and support strategies almost certainly helped reduce U.S. deaths when COVID-19 spiked for a second time this summer.
“It’s true that having drugs like remdesivir and steroids is very helpful, [but] we don’t want to forget about the importance of good medical care and critical care,” says Helen Boucher, the chief of geographic medicine and infectious diseases at Tufts Medical Center in Boston, Massachusetts. “It’s even more important than ever that our health-care system can work.”
Take invasive ventilation. The procedure has saved many COVID-19 patients, but it’s not without risk: Pressure from ventilation can cause damage to the lungs, and the shock and discomfort of the situation—having a tube inserted down the windpipe, worrying about one’s survival—can cause symptoms of post-traumatic stress disorder. So researchers have been looking at ways to limit the damage and distress of intubation and use less invasive methods to improve patients’ breathing and blood oxygen levels.
Christian Bime, a researcher and ICU medical director at the University of Arizona – points to the surprising success of another straightforward technique: laying COVID-19 patients on their stomachs. “That’s one of the things we’ve found very, very helpful in COVID patients across the board,” he says.
Lying stomach-down—also known as prone positioning—improves the lungs’ ability to get oxygen into the blood. The heart sits in the front of the chest, so flipping someone onto their stomach takes the weight of the heart off of the lungs. The back of the lungs also have better blood flow and more gas-exchange chambers than the front, which means that when someone’s lying stomach-down, these chambers are less compressed and work more effectively.
“You want blood flow and gas exchange to line up nicely, and putting someone in the prone position maximizes that effect,” says Kevin McGurk, a chief emergency medicine resident at Cook County Health in Chicago, Illinois.
https://www.nationalgeographic.com/science/2020/08/these-promising-coronavirus-treatments-are-saving-lives-cvd/HELP US SPREAD GOOD NEWS!
I run this site in my spare time and thoroughly enjoy giving you all positive news! If you’ve enjoyed the site we’d love for you to help me share the good news far and wide, share us on Reddit, your Facebook or your Twitter and spread a little positivity around.
ENJOY FEEL GOOD, INSPIRING STORIES AND VIDEOS ?
Our new page here is just what you need, with just good news, feel good stories unrelated to COVID.
